Methylation-Based Therapies for Colorectal Cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Colorectal cancer (CRC) arises from accumulated genetic and epigenetic changes.
• Epigenetic alterations, specifically DNA methylation, are now classified as CRC molecular subtypes, indicating prognostic significance.
• Epigenetic modifications are reversible, presenting potential therapeutic targets.

Purpose of the Study:

• To review colorectal cancer treatments based on DNA methylation status.
• To evaluate the predictive value of DNA methylation in CRC therapy outcomes.
• To discuss the development of DNA methyltransferase (DNMT) inhibitors for CRC treatment.

Main Methods:

• Literature review of studies on CRC treatment and DNA methylation.
• Analysis of therapy outcomes correlated with patient methylation status.
• Summary of current research on DNMT inhibitors.

Main Results:

• DNA methylation status has predictive value for CRC treatment response.
• Inter-individual differences in therapy response are linked to specific (epi)genetic profiles.
• DNMT inhibitors are a promising therapeutic avenue, particularly for hypermethylated CRC.

Conclusions:

• DNA methylation is integral to CRC etiology, evolution, and treatment response.
• Targeting DNA methylation through DNMT inhibitors represents a novel therapeutic strategy for CRC.
• Personalized CRC treatment strategies incorporating DNA methylation analysis are essential for improved patient outcomes.